{"id":"https://openalex.org/W2092118732","doi":"https://doi.org/10.1016/j.vaccine.2014.03.040","title":"Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials","display_name":"Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials","publication_year":2014,"publication_date":"2014-03-25","ids":{"openalex":"https://openalex.org/W2092118732","doi":"https://doi.org/10.1016/j.vaccine.2014.03.040","mag":"2092118732","pmid":"https://pubmed.ncbi.nlm.nih.gov/24674663"},"language":"en","primary_location":{"id":"doi:10.1016/j.vaccine.2014.03.040","doi":"https://doi.org/10.1016/j.vaccine.2014.03.040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.vaccine.2014.03.040","pdf_url":null,"source":{"id":"https://openalex.org/S27359860","display_name":"Vaccine","issn_l":"0264-410X","issn":["0264-410X","1873-2518"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-200","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.vaccine.2014.03.040","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034878566","display_name":"Pierre Van Damme","orcid":"https://orcid.org/0000-0002-8642-1249","observed_orcids":["https://orcid.org/0000-0002-8642-1249"]},"institutions":[{"id":"https://openalex.org/I149213910","display_name":"University of Antwerp","ror":"https://ror.org/008x57b05","country_code":"BE","type":"education","lineage":["https://openalex.org/I149213910"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Pierre Van Damme","raw_affiliation_strings":["Universiteit Antwerpen, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Building R, 2nd Floor, Universiteitsplein 1, 2610 Antwerpen, Belgium. Electronic address: pierre.vandamme@ua.ac.be","Universiteit Antwerpen, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Building R, 2nd Floor, Universiteitsplein 1, 2610 Antwerpen, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universiteit Antwerpen, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Building R, 2nd Floor, Universiteitsplein 1, 2610 Antwerpen, Belgium. Electronic address: pierre.vandamme@ua.ac.be","institution_ids":["https://openalex.org/I149213910"]},{"raw_affiliation_string":"Universiteit Antwerpen, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Building R, 2nd Floor, Universiteitsplein 1, 2610 Antwerpen, Belgium","institution_ids":["https://openalex.org/I149213910"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056800707","display_name":"Geert G Leroux-Roels","orcid":"https://orcid.org/0000-0001-5968-2542","observed_orcids":["https://orcid.org/0000-0001-5968-2542"]},"institutions":[{"id":"https://openalex.org/I2801227569","display_name":"Ghent University Hospital","ror":"https://ror.org/00xmkp704","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801227569"]},{"id":"https://openalex.org/I32597200","display_name":"Ghent University","ror":"https://ror.org/00cv9y106","country_code":"BE","type":"education","lineage":["https://openalex.org/I32597200"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Geert Leroux-Roels","raw_affiliation_strings":["Center for Vaccinology, Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: geert.lerouxroels@ugent.be","Center for Vaccinology, Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Vaccinology, Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: geert.lerouxroels@ugent.be","institution_ids":["https://openalex.org/I2801227569","https://openalex.org/I32597200"]},{"raw_affiliation_string":"Center for Vaccinology, Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium","institution_ids":["https://openalex.org/I2801227569","https://openalex.org/I32597200"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102706971","display_name":"Philippe Simon","orcid":"https://orcid.org/0000-0002-6982-1873","observed_orcids":["https://orcid.org/0000-0002-6982-1873"]},"institutions":[{"id":"https://openalex.org/I2802054198","display_name":"Erasmus Hospital","ror":"https://ror.org/05j1gs298","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2802054198"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Philippe Simon","raw_affiliation_strings":["Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Erasme, Route de Lennik 808, 1070 Bruxelles, Belgium. Electronic address: philippe.simon@erasme.ulb.ac.be","Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Erasme, Route de Lennik 808, 1070 Bruxelles, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Erasme, Route de Lennik 808, 1070 Bruxelles, Belgium. Electronic address: philippe.simon@erasme.ulb.ac.be","institution_ids":["https://openalex.org/I2802054198"]},{"raw_affiliation_string":"Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Erasme, Route de Lennik 808, 1070 Bruxelles, Belgium","institution_ids":["https://openalex.org/I2802054198"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062387212","display_name":"Jean\u2010Michel Foidart","orcid":"https://orcid.org/0000-0001-8285-3573","observed_orcids":["https://orcid.org/0000-0001-8285-3573"]},"institutions":[{"id":"https://openalex.org/I4210159123","display_name":"Centre hospitalier r\u00e9gional de la Citadelle","ror":"https://ror.org/059kfmf89","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4210159123"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Jean-Michel Foidart","raw_affiliation_strings":["CHR Citadelle, Service de Gyn\u00e9cologie Obst\u00e9trique, Boulevard du 12ieme de Ligne 1, 4000 Li\u00e8ge, Belgium. Electronic address: jmfoidart@ulg.ac.be","CHR Citadelle, Service de Gyn\u00e9cologie Obst\u00e9trique, Boulevard du 12ieme de Ligne 1, 4000 Li\u00e8ge, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHR Citadelle, Service de Gyn\u00e9cologie Obst\u00e9trique, Boulevard du 12ieme de Ligne 1, 4000 Li\u00e8ge, Belgium. Electronic address: jmfoidart@ulg.ac.be","institution_ids":["https://openalex.org/I4210159123"]},{"raw_affiliation_string":"CHR Citadelle, Service de Gyn\u00e9cologie Obst\u00e9trique, Boulevard du 12ieme de Ligne 1, 4000 Li\u00e8ge, Belgium","institution_ids":["https://openalex.org/I4210159123"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003323285","display_name":"Gilbert G.G. Donders","orcid":"https://orcid.org/0000-0001-9890-6254","observed_orcids":["https://orcid.org/0000-0001-9890-6254"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gilbert Donders","raw_affiliation_strings":["Gynaecologie, Heilig Hartziekenhuis, Kliniekstraat 45, 3300 Tienen, Belgium. Electronic address: gilbert.donders@femicare.net","Gynaecologie, Heilig Hartziekenhuis, Kliniekstraat 45, 3300 Tienen, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gynaecologie, Heilig Hartziekenhuis, Kliniekstraat 45, 3300 Tienen, Belgium. Electronic address: gilbert.donders@femicare.net","institution_ids":[]},{"raw_affiliation_string":"Gynaecologie, Heilig Hartziekenhuis, Kliniekstraat 45, 3300 Tienen, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035204811","display_name":"Karel Hoppenbrouwers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Karel Hoppenbrouwers","raw_affiliation_strings":["KULeuven, Jeugdgezondheidszorg, Kapucijnvoer 35/1, 3000 Leuven, Belgium. Electronic address: karel.hoppenbrouwers@med.kuleuven.be","KULeuven, Jeugdgezondheidszorg, Kapucijnvoer 35/1, 3000 Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"KULeuven, Jeugdgezondheidszorg, Kapucijnvoer 35/1, 3000 Leuven, Belgium. Electronic address: karel.hoppenbrouwers@med.kuleuven.be","institution_ids":["https://openalex.org/I99464096"]},{"raw_affiliation_string":"KULeuven, Jeugdgezondheidszorg, Kapucijnvoer 35/1, 3000 Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051264386","display_name":"Myron J. Levin","orcid":"https://orcid.org/0000-0002-7468-106X","observed_orcids":["https://orcid.org/0000-0002-7468-106X"]},"institutions":[{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]},{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Myron Levin","raw_affiliation_strings":["University of Colorado School of Medicine, Building 401, 1784 Racine St., Aurora, CO 80045, USA. Electronic address: Myron.Levin@ucdenver.edu","University of Colorado School of Medicine, Building 401, 1784 Racine St., Aurora, CO 80045, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado School of Medicine, Building 401, 1784 Racine St., Aurora, CO 80045, USA. Electronic address: Myron.Levin@ucdenver.edu","institution_ids":["https://openalex.org/I51713134","https://openalex.org/I921990950"]},{"raw_affiliation_string":"University of Colorado School of Medicine, Building 401, 1784 Racine St., Aurora, CO 80045, USA","institution_ids":["https://openalex.org/I51713134"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110180434","display_name":"Fabia\u0301n S. Tibaldi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Fabian Tibaldi","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: fabian.s.tibaldi@gsk.com","GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: fabian.s.tibaldi@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008813104","display_name":"Sylviane M. Poncelet","orcid":"https://orcid.org/0000-0002-2279-5444","observed_orcids":["https://orcid.org/0000-0002-2279-5444"]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Sylviane Poncelet","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sylviane.poncelet@gsk.com","GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sylviane.poncelet@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109008301","display_name":"Philippe Moris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Philippe Moris","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: philippe.moris@gsk.com","GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: philippe.moris@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107413013","display_name":"Francis J. Dessy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Francis Dessy","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: francis.dessy@gsk.com","GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: francis.dessy@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011550497","display_name":"Sandra L. Giannini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Sandra L. Giannini","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sandra.giannini@gsk.com","GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sandra.giannini@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Rue De L\u2018institut 89, 1330 Rixensart, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024245378","display_name":"Dominique Descamps","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095529","display_name":"GlaxoSmithKline (Belgium)","ror":"https://ror.org/00n3pea85","country_code":"BE","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210095529"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Dominique Descamps","raw_affiliation_strings":["GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: dominique.descamps@gsk.com","GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: dominique.descamps@gsk.com","institution_ids":["https://openalex.org/I4210095529"]},{"raw_affiliation_string":"GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium","institution_ids":["https://openalex.org/I4210095529"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019152388","display_name":"Gary O. Dubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Dubin","raw_affiliation_strings":["GlaxoSmithKline SA, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA. Electronic address: Gary.O.Dubin@gsk.com","GlaxoSmithKline SA, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline SA, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA. Electronic address: Gary.O.Dubin@gsk.com","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline SA, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5034878566"],"corresponding_institution_ids":["https://openalex.org/I149213910"],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":{"value":3620,"currency":"USD","value_usd":3620},"fwci":3.0202,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.90779752,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"32","issue":"29","first_page":"3694","last_page":"3705"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10146","display_name":"Cervical Cancer and HPV Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10146","display_name":"Cervical Cancer and HPV Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/human-papillomavirus-vaccine","display_name":"HPV vaccine","score":0.8930000066757202},{"id":"https://openalex.org/keywords/l1-virus-like-particles","display_name":"L1 virus-like particles","score":0.8019999861717224},{"id":"https://openalex.org/keywords/as04-adjuvant","display_name":"AS04 adjuvant","score":0.8600000143051147},{"id":"https://openalex.org/keywords/as01-adjuvant","display_name":"AS01 adjuvant","score":0.925000011920929},{"id":"https://openalex.org/keywords/hpv-16","display_name":"HPV16","score":0.7319999933242798},{"id":"https://openalex.org/keywords/hpv-18","display_name":"HPV 18","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hpv-31","display_name":"HPV 31","score":0.9660000205039978},{"id":"https://openalex.org/keywords/hpv-45","display_name":"HPV45","score":0.9319999814033508},{"id":"https://openalex.org/keywords/hpv-33","display_name":"HPV 33","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hpv-58","display_name":"HPV58","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.7480000257492065},{"id":"https://openalex.org/keywords/vaccine-safety","display_name":"vaccine safety","score":0.8529999852180481},{"id":"https://openalex.org/keywords/immune-interference","display_name":"immune interference","score":0.8690000176429749},{"id":"https://openalex.org/keywords/antibody-titers","display_name":"antibody titers","score":0.6629999876022339},{"id":"https://openalex.org/keywords/memory-b-cells","display_name":"memory B cells","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cd4-t-cell-responses","display_name":"CD4+ T cell responses","score":0.847000002861023},{"id":"https://openalex.org/keywords/vaccination-schedule","display_name":"vaccination schedule","score":0.48899999260902405}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.8659697771072388},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.7960197925567627},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6958822011947632},{"id":"https://openalex.org/C2780009117","wikidata":"https://www.wikidata.org/wiki/Q900189","display_name":"HPV vaccines","level":5,"score":0.6679370999336243},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5433109998703003},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5062662363052368},{"id":"https://openalex.org/C2778220009","wikidata":"https://www.wikidata.org/wiki/Q160105","display_name":"Cervical cancer","level":3,"score":0.45288020372390747},{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.44077953696250916},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4272737205028534},{"id":"https://openalex.org/C2776387124","wikidata":"https://www.wikidata.org/wiki/Q1475781","display_name":"Virus-like particle","level":4,"score":0.4214043915271759},{"id":"https://openalex.org/C3018913218","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody response","level":3,"score":0.41197696328163147},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3590124845504761},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3426976203918457},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3199678659439087},{"id":"https://openalex.org/C2778580637","wikidata":"https://www.wikidata.org/wiki/Q184627","display_name":"HPV infection","level":4,"score":0.23731034994125366},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1628466248512268},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.07433333992958069},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000276","descriptor_name":"Adjuvants, Immunologic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000917","descriptor_name":"Antibody Formation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000956","descriptor_name":"Antigens, Viral","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D001402","descriptor_name":"B-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D001530","descriptor_name":"Belgium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D004306","descriptor_name":"Dose-Response Relationship, Immunologic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007156","descriptor_name":"Immunologic Memory","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D030361","descriptor_name":"Papillomavirus Infections","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D052161","descriptor_name":"Human papillomavirus 18","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052162","descriptor_name":"Human papillomavirus 16","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053918","descriptor_name":"Papillomavirus Vaccines","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D053918","descriptor_name":"Papillomavirus Vaccines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058425","descriptor_name":"Vaccines, Virus-Like Particle","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D058425","descriptor_name":"Vaccines, Virus-Like Particle","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1016/j.vaccine.2014.03.040","doi":"https://doi.org/10.1016/j.vaccine.2014.03.040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.vaccine.2014.03.040","pdf_url":null,"source":{"id":"https://openalex.org/S27359860","display_name":"Vaccine","issn_l":"0264-410X","issn":["0264-410X","1873-2518"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-200","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"journal-article"},{"id":"pmid:24674663","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24674663","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:archive.ugent.be:6830500","doi":null,"is_oa":false,"landing_page_url":"https://biblio.ugent.be/publication/6830500","pdf_url":null,"source":{"id":"https://openalex.org/S4306400478","display_name":"Ghent University Academic Bibliography (Ghent University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I32597200","host_organization_name":"Ghent University","host_organization_lineage":["https://openalex.org/I32597200"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ISSN: 0264-410X","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:dipot.ulb.ac.be:2013/192418","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/192418","pdf_url":null,"source":{"id":"https://openalex.org/S4306401063","display_name":"D\u00e9p\u00f4t institutionnel de l'Universit\u00e9 libre de Bruxelles (Universit\u00e9 Libre de Bruxelles)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I132053463","host_organization_name":"Universit\u00e9 Libre de Bruxelles","host_organization_lineage":["https://openalex.org/I132053463"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Vaccine, 32 (29","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:orbi.ulg.ac.be:2268/165704","doi":null,"is_oa":false,"landing_page_url":"https://orbi.uliege.be/handle/2268/165704","pdf_url":null,"source":{"id":"https://openalex.org/S4306401300","display_name":"ORBi (University of Li\u00e8ge)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I157674565","host_organization_name":"University of Li\u00e8ge","host_organization_lineage":["https://openalex.org/I157674565"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Vaccine (2014)","raw_type":"http://purl.org/coar/resource_type/c_6501"}],"best_oa_location":{"id":"doi:10.1016/j.vaccine.2014.03.040","doi":"https://doi.org/10.1016/j.vaccine.2014.03.040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.vaccine.2014.03.040","pdf_url":null,"source":{"id":"https://openalex.org/S27359860","display_name":"Vaccine","issn_l":"0264-410X","issn":["0264-410X","1873-2518"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-200","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vaccine","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320322603","display_name":"Universiteit Gent","ror":"https://ror.org/00cv9y106"},{"id":"https://openalex.org/F4320324595","display_name":"Universiteit Antwerpen","ror":"https://ror.org/008x57b05"},{"id":"https://openalex.org/F8449784507","display_name":"GlaxoSmithKline Biologicals","ror":"https://ror.org/00n3pea85"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1956712871","https://openalex.org/W1964927845","https://openalex.org/W1979230907","https://openalex.org/W1979240321","https://openalex.org/W1981989535","https://openalex.org/W1987045012","https://openalex.org/W1987350137","https://openalex.org/W2001429203","https://openalex.org/W2017096286","https://openalex.org/W2018558581","https://openalex.org/W2020386919","https://openalex.org/W2021614645","https://openalex.org/W2056646243","https://openalex.org/W2060084556","https://openalex.org/W2072761990","https://openalex.org/W2072881891","https://openalex.org/W2081619150","https://openalex.org/W2091307968","https://openalex.org/W2092080866","https://openalex.org/W2102245223","https://openalex.org/W2114391710","https://openalex.org/W2123962939","https://openalex.org/W2135671488","https://openalex.org/W2136236728","https://openalex.org/W2148639070","https://openalex.org/W2149883005","https://openalex.org/W2150436558","https://openalex.org/W2159831861","https://openalex.org/W2166678252","https://openalex.org/W2167885314","https://openalex.org/W3151241602","https://openalex.org/W4239606454","https://openalex.org/W4248862225","https://openalex.org/W6823862582"],"related_works":["https://openalex.org/W1933192471","https://openalex.org/W4220904869","https://openalex.org/W1964375899","https://openalex.org/W2769604813","https://openalex.org/W2154262967","https://openalex.org/W1988984928","https://openalex.org/W2119984240","https://openalex.org/W2332729004","https://openalex.org/W2159831861","https://openalex.org/W4239392382"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1],"prophylactic":[2],"human":[3],"papillomavirus":[4],"(HPV)":[5],"vaccine":[6,58,80,159,175],"targeting":[7],"oncogenic":[8,51],"HPV":[9,40,271],"types":[10],"in":[11,60,242],"addition":[12],"to":[13,31,248,276],"HPV-16":[14,190,262],"and":[15,35,136,167,170,191,238,263],"-18":[16,137,264],"may":[17],"broaden":[18],"protection":[19],"against":[20],"cervical":[21],"cancer.":[22],"Two":[23],"Phase":[24],"I/II,":[25],"randomized,":[26],"controlled":[27],"studies":[28],"were":[29,151,205,267,274],"conducted":[30],"compare":[32],"the":[33,54,123,220,243,251,277,294],"immunogenicity":[34],"safety":[36,239],"of":[37,75,96,222,253],"investigational":[38],"tetravalent":[39,77,98,144,197],"L1":[41,224,272],"virus-like":[42],"particle":[43],"(VLP)":[44],"vaccines,":[45],"containing":[46,160,176,259],"VLPs":[47,163,179,225,273],"from":[48],"two":[49],"additional":[50,254,270],"genotypes,":[52],"with":[53,102,148,250],"licensed":[55],"HPV-16/18":[56,223,278],"AS04-adjuvanted":[57,145,279],"(control)":[59],"healthy":[61],"18-25":[62],"year-old":[63],"women.":[64],"METHODS:":[65],"In":[66,86],"one":[67,74,95],"trial":[68,89],"(NCT00231413),":[69],"subjects":[70,91],"received":[71,92],"control":[72,93],"or":[73,94,108,115,117,226,297],"6":[76],"HPV-16/18/31/45":[78,157],"AS04":[79,158,174,198],"formulations":[81,234,258],"at":[82],"months":[83],"(M)":[84],"0,1,6.":[85],"a":[87,130,186,229,284],"second":[88],"(NCT00478621),":[90],"5":[97],"HPV-16/18/33/58":[99,173],"vaccines":[100,146,199],"formulated":[101],"different":[103,112,230],"adjuvant":[104,231,298],"systems":[105],"(AS04,":[106],"AS01":[107],"AS02),":[109],"administered":[110],"on":[111],"schedules":[113],"(M0,1,6":[114],"M0,3":[116],"M0,6).":[118],"RESULTS:":[119],"One":[120],"month":[121],"after":[122],"third":[124],"injection":[125],"(Month":[126],"7),":[127],"there":[128],"was":[129,184],"consistent":[131],"trend":[132,187],"for":[133,143,155,164,171,180,188,196,207,257],"lower":[134,154,189,268],"anti-HPV-16":[135,166,181],"geometric":[138],"mean":[139],"antibody":[140,265],"titers":[141],"(GMTs)":[142],"compared":[147],"control.":[149,201],"GMTs":[150],"statistically":[152],"significantly":[153],"an":[156,172],"20/20/10/10":[161],"\u03bcg":[162,178],"both":[165],"anti-HPV-18":[168],"antibodies,":[169],"20/20/20/20":[177],"antibodies.":[182],"There":[183],"also":[185],"-18-specific":[192],"memory":[193],"B-cell":[194],"responses":[195,266],"versus":[200],"No":[202],"such":[203],"trends":[204],"observed":[206],"CD4(+)":[208],"T-cell":[209],"responses.":[210],"Immune":[211,281],"interference":[212,282],"could":[213],"not":[214],"always":[215,289],"be":[216,290],"overcome":[217,291],"by":[218,227,292],"increasing":[219],"dose":[221,296],"using":[228],"system.":[232,299],"All":[233],"had":[235],"acceptable":[236],"reactogenicity":[237],"profiles.":[240],"Reactogenicity":[241],"7-day":[244],"post-vaccination":[245],"period":[246],"tended":[247],"increase":[249],"introduction":[252],"VLPs,":[255],"especially":[256],"AS01.":[260],"CONCLUSIONS:":[261],"when":[269],"added":[275],"vaccine.":[280],"is":[283],"complex":[285],"phenomenon":[286],"that":[287],"cannot":[288],"changing":[293],"antigen":[295]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}